Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD

INTRODUCTION: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that has demonstrated safety and efficacy versus placebo in phase III trials in patients with anemia of chronic kidney disease (CKD) who were not on dialysis (NDD). METHODS: This was a phase III, active-control...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Kidney Int Rep
Main Authors: Akizawa, Tadao, Iwasaki, Manabu, Otsuka, Tetsuro, Yamaguchi, Yusuke, Reusch, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2021
Assuntos:
Clinical Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8258605/
https://ncbi.nlm.nih.gov/pubmed/34307976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ekir.2021.04.003
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares